Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a clinical study titled ‘A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Dose Topical Administration of PF-07905428 in Healthy Participants and Participants With Acne Vulgaris.’ The study aims to assess the safety and effectiveness of PF-07905428, a topical treatment for acne vulgaris, in individuals aged 18 to 40.
The intervention being tested is PF-07905428, a topical drug applied daily in varying strengths (0.08% and 0.24%) to treat acne vulgaris. The study also includes a placebo group for comparison.
This Phase 1 study is randomized and double-blind, meaning participants and investigators do not know who receives the treatment or placebo. It follows a parallel intervention model with the primary purpose of treatment.
The study began on October 18, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on September 2, 2025, indicating ongoing recruitment.
The potential success of PF-07905428 could positively impact Pfizer’s stock by expanding its dermatology portfolio, enhancing investor confidence. Competitors in the acne treatment market may also feel pressure to innovate.
The study is currently ongoing, with further details available on the ClinicalTrials portal.